Cardiff Oncology, Inc.CRDFEarnings & Financial Report
Nasdaq
NextMar 30, 2026
CRDF Q3 2025 Key Financial Metrics
Revenue
$120.0K
Gross Profit
N/A
Operating Profit
$-12.0M
Net Profit
$-11.3M
Gross Margin
N/A
Operating Margin
-9978.3%
Net Margin
-9381.7%
YoY Growth
-27.3%
EPS
$-0.17
Financial Flow
Cardiff Oncology, Inc. Q3 2025 Financial Summary
Cardiff Oncology, Inc. reported revenue of $120.0K for Q3 2025, with a net profit of $-11.3M (-9381.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $120.0K |
|---|---|
| Net Profit | $-11.3M |
| Gross Margin | N/A |
| Operating Margin | -9978.3% |
| Report Period | Q3 2025 |
Cardiff Oncology, Inc. Annual Revenue by Year
Cardiff Oncology, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $683.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $683.0K |
| 2023 | $488.0K |
| 2022 | $386.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $156000 | $205000 | $163000 | $165000 | $150000 | $109000 | $121000 | $120000 |
| YoY Growth | 21.9% | 147.0% | 50.9% | 17.0% | -3.8% | -46.8% | -25.8% | -27.3% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $81.6M | $74.0M | $66.1M | $62.9M | $97.2M | $84.8M | $75.7M | $63.8M |
| Liabilities | $11.9M | $13.1M | $13.7M | $13.5M | $14.2M | $13.9M | $17.1M | $15.0M |
| Equity | $69.7M | $60.9M | $52.4M | $49.4M | $82.9M | $70.9M | $58.6M | $48.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.1M | $-7.7M | $-9.2M | $-10.5M | $-10.3M | $-12.8M | $-8.3M | $-10.8M |